Insulin Glargine: a review 8 years after its introduction

Bibliography

• Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the treatment of diabetes mellitus. CMAJ 1922;12:141-6
   PubMedGoogle Scholar
• Hagedorn HC, Jensen BN, Krarup NB, Woodstrup I. Protamine insulin. JAMA 1936;177-80
   Google Scholar
• Hallas-Moller K, Jersild M, Petersen K, Schlichtkrull J. The lente insulins, insulin-zinc suspensions. Dan Med Bull 1954;1:132-42
   PubMedGoogle Scholar
• Murray I, Wilson RB. The new insulins-lente, ultralente, and semilente. Br Med J 1953;2:1023-6
   PubMedGoogle Scholar
• Olsson PO, Hans A, Henning VS. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin. Diabetes Care 1987;10:473-7
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog Glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8
   PubMed Web of Science ®Google Scholar
• Jackson RL. Historical background. In: Guthrie RA, editor. The physiologic management of diabetes in children. New York: Medical examination publishing company, 1986. p. 6-16
   Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83
   PubMed Web of Science ®Google Scholar
• Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999;22(Suppl 2):B109-13
   PubMedGoogle Scholar
• Bahr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997;320:259-65
   PubMed Web of Science ®Google Scholar
• Lantus [prescribing information]. Bridgewater NJ, 2007. Available from: http://products.sanofi-aventis.us/lantus/lantus.html [Last accessed 21 April 2008]
   Google Scholar
• Lantus. FDA Approval documentation, 2000. Available from: http://www.fda.gov/cder/foi/label/2000/21081lbl.pdf [Last accessed 17 September 2008]
   Google Scholar
• Bolli GB, Owens DR. Insulin Glargine. Lancet 2000;356:443-5
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin Glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6
   PubMed Web of Science ®Google Scholar
• Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125I-labeled insulin Glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000;23:813-19
   PubMed Web of Science ®Google Scholar
• Rave K, Heise T, Heinemann L. Time-action profile of insulin Glargine (HOE 901) in Japanese volunteers. Diabetes 2000:A363
   Google Scholar
• Heise T, Bott S, Rave K, et al. No evidence for accumulation of insulin Glargine (LANTUS): a multiple injection study in patients with type 1 diabetes. Diabet Med 2002;19:490-5
   PubMed Web of Science ®Google Scholar
• Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin Glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005;48:1988-95
   PubMed Web of Science ®Google Scholar
• Kudva YC, Basu A, Jenkins GD, et al. Randomized controlled clinical trial of Glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005;28:10-14
   PubMed Web of Science ®Google Scholar
• Peter R, Luzio SD, Dunseath G, et al. Effects of exercise on the absorption of insulin Glargine in patients with type 1 diabetes. Diabetes Care 2005;28:560-5
   PubMed Web of Science ®Google Scholar
• Kaplan W, Rodriguez LM, Smith OE, et al. Effects of mixing Glargine and short-acting insulin analogs on glucose control. Diabetes Care 2004;27:2739-40
   PubMed Web of Science ®Google Scholar
• Fiallo-Scharer R, Horner B, McFann K, et al. Mixing rapid-acting insulin analogues with insulin Glargine in children with type 1 diabetes mellitus. J Pediatr 2006;148:481-4
   PubMed Web of Science ®Google Scholar
• Hassan K, Rodriguez LM, Johnson SE. A randomized, controlled trial comparing twice-a-day insulin Glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics 2008;121:466-72
   Google Scholar
• Milazzo G, Sciacca L, Papa V, et al. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 1997;18:19-25
   PubMed Web of Science ®Google Scholar
• Shymko RM, Dumont E, De Meyts P, Dumont JE. Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 1999;339:675-83
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005
   PubMed Web of Science ®Google Scholar
• Slawik M, Schories M, Busse Grawitz A, et al. Treatment with insulin Glargine does not suppress serum IGF-1. Diabet Med 2006;23:814-17
   PubMed Web of Science ®Google Scholar
• Staiger K, Hennige AM, Staiger H, et al. Comparison of the mitogenic potency of regular human insulin and its analogue Glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007;39:65-7
   PubMed Web of Science ®Google Scholar
• Stammberger I, Bube A, Durchfeld-Meyer B, et al. Evaluation of the carcinogenic potential of insulin Glargine (LANTUS) in rats and mice. Int J Toxicol 2002;21:171-9
   PubMed Web of Science ®Google Scholar
• Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390-5
   PubMed Web of Science ®Google Scholar
• Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998;82:725-30
   PubMed Web of Science ®Google Scholar
• Henricsson M, Berntorp K, Fernlund P, Sundkvist G. Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care 2002;25:381-5
   PubMed Web of Science ®Google Scholar
• Davis MD, Beck RW, Home PD, et al. Early retinopathy progression in four randomized trials comparing insulin Glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes 2007;115:240-3
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Fonseca V, MacGill J, et al. Similar progression of diabetic retinopathy with insulin Glargine or NPH insulin in type 2 diabetes. 301-0R. American Diabetes Association Annual Meeting, 6-10 June 2008; San Francisco, USA
   Google Scholar
• Graves DE, White JC, Kirk JK. The use of insulin Glargine with gestational diabetes mellitus. Diabetes Care 2006;29:471-2
   PubMed Web of Science ®Google Scholar
• Price N, Bartlett C, Gillmer M. Use of insulin Glargine during pregnancy: a case-control pilot study. BJOG 2007;114:453-7
   PubMed Web of Science ®Google Scholar
• Poyhonen-Alho M, Ronnemaa T, Saltevo J, et al. Use of insulin Glargine during pregnancy. Acta Obstet Gynecol Scand 2007;1:1-4
   Google Scholar
• Radermecker RP, Scheen AJ. Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev 2007;23:348-55
   PubMed Web of Science ®Google Scholar
• Karges B, Muche R, Riegger I, et al. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. Clin Ther 2006;28:2094-101
   PubMed Web of Science ®Google Scholar
• McKeage K, Goa KL. Insulin Glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001;61:1599-624
   PubMed Web of Science ®Google Scholar
• Wang F, Carabino JM, Vergara CM. Insulin Glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003;25:1541-77; discussion 1539-40
   PubMed Web of Science ®Google Scholar
• McKeage K, Goa KL. Spotlight on insulin Glargine in type 1 and 2 diabetes mellitus. Treat Endocrinol 2002;1:55-8
   PubMedGoogle Scholar
• Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005;35:536-42
   PubMed Web of Science ®Google Scholar
• Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and Glargine insulin at dinner or bedtime. Diabetes Care 2003;26:1490-6
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Jarvis-Kay J, Rengarajan T, et al. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes – the Glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract 2007;77:215-22
   PubMed Web of Science ®Google Scholar
• Herwig J, Scholl-Schilling G, Bohles H. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin Glargine or intermediate-acting insulin. J Pediatr Endocrinol Metab 2007;20:517-25
   PubMed Web of Science ®Google Scholar
• Roach P, Bai S, Charbonnel B, et al. Effects of multiple daily injection therapy with humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Clin Ther 2004;26:502-10
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin Glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554-9
   PubMed Web of Science ®Google Scholar
• Buckingham RE, Hanna A. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Diabetes Obes Metab 2008;10:312-28
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Avandia (rosiglitazone) [package insert]. Philadelphia, PA: SmithKline Beecham Pharmaceuticals, 2007. Available from: www.fda.gov/cder/foi/label/2007/021071s031lbl.pdf [Last accessed 24 September 2008]
   Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study Group. JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Lindstrom T, Eriksson P, Olsson AG, Arnqvist HJ. Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure. Diabetes Care 1994;17:719-21
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-9
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin Glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51
   PubMed Web of Science ®Google Scholar
• Schreiber SA, Haak T. Insulin Glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007;9:31-8
   PubMed Web of Science ®Google Scholar
• Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-9
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin Glargine: a meta-analysis comparing insulin Glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-5
   PubMed Web of Science ®Google Scholar
• Malone JK, Kerr LF, Campaigne BN, et al.; Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin Glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-44
   PubMed Web of Science ®Google Scholar
• Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007;29:1254-70
   Web of Science ®Google Scholar
• Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al.; Action To Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin Glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin Glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20
   PubMed Web of Science ®Google Scholar
• Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin Glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-9
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin Glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med 2006;23:879-86
   PubMed Web of Science ®Google Scholar
• Albright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin Glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004;27:632-3
   PubMed Web of Science ®Google Scholar
• Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23:441-54
   PubMed Web of Science ®Google Scholar
• Grimaldi A, Vialettes B, Blayo A, et al. Comparison of dinner with bedtime administration of insulin Glargine in type 1 diabetic patients treated with basal-bolus regimen. Diabetes Metab 2007;33:121-8
   PubMed Web of Science ®Google Scholar
• Standl E, Maxeiner S, Raptis S; HOE901/4009 Study Group. Once-daily insulin Glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006;38:172-7
   PubMed Web of Science ®Google Scholar
• Hamann A, Matthaei S, Rosak C, Silvestre L; HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin Glargine in patients with type 1 diabetes. Diabetes Care 2003;26:1738-44
   PubMed Web of Science ®Google Scholar
• Houlden R, Ross S, Harris S, et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin Glargine compared to an adjusted oral therapy in the management of type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 2007;78:254-8
   PubMed Web of Science ®Google Scholar
• Manini R, Forlani G, Moscatiello S, et al. Insulin Glargine improves glycemic control and health-related quality of life in type 1 diabetes. Nutr Metab Cardiovasc Dis 2007;17:493-8
   PubMed Web of Science ®Google Scholar
• Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin Glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001;18:619-25
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia E, Galera R, Aguilera P, et al. Long-term use of continuous subcutaneous insulin infusion compared with multiple daily injections of Glargine in pediatric patients. J Pediatr Endocrinol Metab 2007;20:37-40
   PubMed Web of Science ®Google Scholar
• Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care 2000;23:1232-5
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin Glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005;28:533-8
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Hochman J, DeVries JH, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004;27:2590-6
   PubMed Web of Science ®Google Scholar
• Garg SK, Walker AJ, Hoff HK, et al. Glycemic parameters with multiple daily injections using insulin Glargine versus insulin pump. Diabetes Technol Ther 2004;6:9-15
   PubMedGoogle Scholar
• Berthe E, Lireux B, Coffin C, et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res 2007;39:224-9
   PubMed Web of Science ®Google Scholar
• Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31(Suppl 2):S140-5
   PubMed Web of Science ®Google Scholar
• Goldman-Levine JD, Lee KW. Insulin detemir – a new basal insulin analog. Ann Pharmacother 2005;39:502-7
   PubMed Web of Science ®Google Scholar
• Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-504
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Insulin detemir [rDNA origin] injection prescribing information. 16 May 2007. Available from: http://www.levemir-us.com/prescribing_information.pdf [Last accessed 30 September 2008]
   Google Scholar
• Jonassen I, Havelund S, Ribel U, et al. Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm Res 2006;23:49-55
   PubMed Web of Science ®Google Scholar
• Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107-12
   PubMed Web of Science ®Google Scholar
• Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs Glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-52
   PubMed Web of Science ®Google Scholar
• Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-7
   PubMed Web of Science ®Google Scholar
• Hompesch M, Troupin B, Heise T, et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab 2006;8:568-73
   PubMed Web of Science ®Google Scholar
• Kolendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006;23:729-35
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Luddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007;61:523-8
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Luddeke HJ, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008;62:659-65
   PubMed Web of Science ®Google Scholar
• Ghosh S, McCann V, Bartle L, et al. Allergy to insulin detemir. Diabet Med 2007;24:1307
   PubMed Web of Science ®Google Scholar
• Sola-Gazagnes A, Pecquet C, M'Bemba J, et al. Type I and type IV allergy to the insulin analogue detemir. Lancet 2007;369:637-8
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007;9:648-59
   PubMed Web of Science ®Google Scholar
• Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin Glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007;24:635-42
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin Glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
   PubMed Web of Science ®Google Scholar
• Colino E, Lopez-Capape M, Golmayo L, et al. Therapy with insulin Glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2005;70:1-7
   PubMed Web of Science ®Google Scholar
• Hathout EH, Fujishige L, Geach J, et al. Effect of therapy with insulin Glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther 2003;5:801-6
   PubMedGoogle Scholar
• Chase HP, Dixon B, Pearson J, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin Glargine and neutral protamine Hagedorn insulin. J Pediatr 2003;143:737-40
   PubMed Web of Science ®Google Scholar
• Tan CY, Wilson DM, Buckingham B. Initiation of insulin Glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes 2004;5:80-6
   PubMed Web of Science ®Google Scholar
• Urakami T, Morimoto S, Kubota S, et al. Usefulness of the long-acting insulin analogue Glargine in basal-bolus therapy for Japanese children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2007;20:807-15
   PubMed Web of Science ®Google Scholar
• Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000;13:4-8
   PubMed Web of Science ®Google Scholar
• Nevalainen PI, Lahtela JT, Mustonen J, Pasternack A. Subcutaneous and intraperitoneal insulin therapy in diabetic patients on CAPD. Perit Dial Int 1996;16(Suppl 1):288-91
   PubMed Web of Science ®Google Scholar
• Jiminez-Vega J, Jones SA, Nazarian S, et al. Glycemic control in end stage renal disease before and after conversion to insulin Glargine [poster P4-160]. Presented at the 89th Annual Meeting of the Endocrine Society, 2–5 June 2007; Toronto, Canada
   Google Scholar
• Exenatide.new drug. Type 2 diabetes for some overweight patients. Prescrire Int 2007;16:228-31
   PubMedGoogle Scholar
• Byetta prescribing information insert. US package insert – draft. 2006. Available from: http://www.fda.gov/cder/foi/label/2005/021773lbl.pdf [Last accessed 19 August 2008]
   Google Scholar
• Guerci B, Martin CS. Exenatide: its position in the treatment of type 2 diabetes. Ann Endocrinol (Paris) 2008;69:201-9
   PubMed Web of Science ®Google Scholar
• Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491-9
   PubMed Web of Science ®Google Scholar
• Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin Glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-22
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin Glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006;29:471
   PubMed Web of Science ®Google Scholar
• Haas LB. Optimizing insulin use in type 2 diabetes: role of basal and prandial insulin in long-term care facilities. J Am Med Dir Assoc 2007;8:502-10
   PubMed Web of Science ®Google Scholar
• Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007;55:182-8
   PubMed Web of Science ®Google Scholar
• Papa G, Fedele V, Chiavetta A, et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin Glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 2008;45:53-9
   PubMed Web of Science ®Google Scholar
• Reed CC, Stewart RM, Sherman M, et al. Intensive insulin protocol improves glucose control and is associated with a reduction in intensive care unit mortality. J Am Coll Surg 2007;204:1048-54; discussion 1054-5
   PubMed Web of Science ®Google Scholar
• D'Alessandro C, Leprince P, Golmard JL, et al. Strict glycemic control reduces EuroSCORE expected mortality in diabetic patients undergoing myocardial revascularization. J Thorac Cardiovasc Surg 2007;134:29-37
   PubMed Web of Science ®Google Scholar
• Braithwaite SS. Inpatient insulin therapy. Curr Opin Endocrinol Diabetes Obes 2008;15:159-66
   PubMedGoogle Scholar
• Hermayer KL, Neal DE, Hushion TV, et al. Outcomes of a cardiothoracic intensive care web-based online intravenous insulin infusion calculator study at a Medical University Hospital. Diabetes Technol Ther 2007;9:523-34
   PubMed Web of Science ®Google Scholar
• Fatati G, Mirri E, Palazzi M, et al. Insulin Glargine in patients with severe hepato-gastroenterology diseases and hyperglycemia receiving parenteral nutrition. Clin Ter 2006;157:511-15
   PubMedGoogle Scholar
• Yeldandi RR, Lurie A, Baldwin D. Comparison of once-daily Glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery. Diabetes Technol Ther 2006;8:609-16
   PubMed Web of Science ®Google Scholar
• Drugstore.com. Insulin price US. 2008. Available from: http://www.drugstore.com/ [Last accessed 20 August 2008]
   Google Scholar
• Rhoads GG, Orsini LS, Crown W, et al. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med 2005;47:447-52
   PubMed Web of Science ®Google Scholar
• Heaton A, Martin S, Brelje T. The economic effect of hypoglycemia in a health plan. Manag Care Interface 2003;16:23-7
   PubMedGoogle Scholar
• Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-8
   PubMed Web of Science ®Google Scholar
• Zhang Q, Menditto L. Incremental cost savings 6 months following initiation of insulin Glargine in a Medicaid fee-for-service sample. Am J Ther 2005;12:337-43
   PubMedGoogle Scholar
• Schwartz S, Sievers R, Strange P, et al; INS-2061 Study Team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003;26:2238-43
   PubMed Web of Science ®Google Scholar